ANI Pharmaceuticals, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +37.0%
EBITDA: +251.0%
EBIT: +1811.6%
EPS: +426.2%
Free cash flow: +226.2%
Operating cash flow: +158.4%

Forward estimates

Revenue: -39.2%
EBITDA: -73.7%
EPS: +23.3%

Three-year CAGR

Revenue: +40.8%
EBITDA: +102.3%
EBIT: +31.5%
Net income: +104.2%
EPS: +91.9%
Free cash flow: +22.6%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.